Ireland's US Exports Jump 52% to €112 Billion, Pharma Sector Leads Growth

This robust performance was heavily influenced by the anticipation and implementation of President Trump's tariffs policy, which prompted US companies to import and stockpile goods from Ireland, particularly in the first three months of 2025. The US solidified its position as Ireland's most crucial export market, absorbing almost 43% of all Irish goods exports in 2025, a notable rise from 33% in the previous year. A primary driver of this export growth was the pharmaceutical sector, with Ireland serving as a major manufacturing hub for global giants such as Pfizer and Eli Lilly.

Medical and pharmaceutical products alone constituted over half, specifically €138.6 billion, of all Irish goods exported in 2025. This growth was partly attributed to the success of drugs like Eli Lilly's weight loss medication, Mounjaro, whose active pharmaceutical ingredient is produced in County Cork.

Despite President Trump's expressed dissatisfaction with the scale of US pharma manufacturing in Ireland and threats of tariffs on these products, most have not been imposed, limiting their direct impact on the sector's overall export performance. The data highlights the complex interplay between trade policy and global supply chains.